Cypherpunk Technologies Inc (CYPH) Stock Price, Quote & News

Company Profile

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an optio...

Industry: Asset Management

Sector: Financial Services

Phone: 617 714 0360

Website: www.leaptx.com

Address:

47 Thorndike Street, Suite B1-1, Cambridge, United States

Dirtbagg Feb. 23 at 4:57 PM

$CYPH restructuring for the Twins? https://x.com/wublockchain/status/2025876034587853249?s=46&t=OQR7dg8UP5Nb9npP2I2IqA

0 · Reply

StockDreamin Feb. 23 at 2:18 PM

$CYPH cypherdrunk

1 · Reply

DubLad76 Feb. 23 at 12:55 PM

$ZEC.X all very positive news in a crypto market under a degree of pressure! Institutional Backing: BitMEX co-founder Arthur Hayes recently revealed ZEC is part of his investment portfolio, signaling confidence in its privacy technology. Network Milestone: Adoption is hitting record highs, with approximately 5 million ZEC (~30% of supply) now held in private, shielded addresses. $CYPH

1 · Reply

Billick5 Feb. 22 at 3:53 PM

$CYPH everything winklevosses touch will go bankrupt

1 · Reply

UgoGreg Feb. 21 at 4:01 PM

$CYPH https://youtu.be/ygBN8MilTyc

0 · Reply

fivehundredpercent Feb. 21 at 3:15 PM

$CYPH they are going to send this next week watch the weekend action

1 · Reply

atechniqueisause Feb. 21 at 12:40 AM

$CYPH Can anyone explain why Winkelvoss invested here and why others should do the same?

1 · Reply

StockDreamin Feb. 20 at 5:28 PM

$CYPH cypherflunk

0 · Reply

DubLad76 Feb. 19 at 10:26 AM

$CYPH let’s be having it! It’s time for some serious action! Annual results coming up soon…. 23rd March people.

1 · Reply

Dirtbagg Feb. 19 at 5:11 AM

$CYPH do I see fity or 40s.

0 · Reply

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Dec 30, 2025, 7:00 AM EST - 7 weeks ago

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Dec 19, 2025, 7:00 AM EST - 2 months ago

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Dec 15, 2025, 12:59 PM EST - 2 months ago

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

Dec 9, 2025, 7:00 AM EST - 2 months ago

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Nov 12, 2025, 8:00 AM EST - 3 months ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 3 months ago

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Oct 20, 2025, 7:00 AM EDT - 4 months ago

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Oct 9, 2025, 7:00 AM EDT - 4 months ago

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Sep 25, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 7:00 AM EDT - 8 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

May 13, 2025, 7:00 AM EDT - 10 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 10 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 11 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Mar 31, 2025, 1:42 PM EDT - 11 months ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 26, 2025, 1:29 PM EDT - 11 months ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 7:05 AM EDT - 11 months ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:00 AM EDT - 11 months ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Jan 28, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 6, 2025, 7:01 AM EST - 1 year ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Leap Therapeutics Announces $40 Million Private Placement

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 16, 2024, 5:05 PM EST - 2 years ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 3, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Dec 11, 2023, 4:05 PM EST - 2 years ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Nov 21, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

May 25, 2023, 5:10 PM EDT - 2 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 15, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Apr 12, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 16, 2023, 4:05 PM EDT - 3 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Jan 17, 2023, 8:00 AM EST - 3 years ago

Leap Therapeutics Acquires Flame Biosciences

Dirtbagg Feb. 23 at 4:57 PM

$CYPH restructuring for the Twins? https://x.com/wublockchain/status/2025876034587853249?s=46&t=OQR7dg8UP5Nb9npP2I2IqA

0 · Reply

StockDreamin Feb. 23 at 2:18 PM

$CYPH cypherdrunk

1 · Reply

DubLad76 Feb. 23 at 12:55 PM

1 · Reply

Billick5 Feb. 22 at 3:53 PM

$CYPH everything winklevosses touch will go bankrupt

1 · Reply

UgoGreg Feb. 21 at 4:01 PM

$CYPH https://youtu.be/ygBN8MilTyc

0 · Reply

fivehundredpercent Feb. 21 at 3:15 PM

$CYPH they are going to send this next week watch the weekend action

1 · Reply

atechniqueisause Feb. 21 at 12:40 AM

$CYPH Can anyone explain why Winkelvoss invested here and why others should do the same?

1 · Reply

StockDreamin Feb. 20 at 5:28 PM

$CYPH cypherflunk

0 · Reply

DubLad76 Feb. 19 at 10:26 AM

$CYPH let’s be having it! It’s time for some serious action! Annual results coming up soon…. 23rd March people.

1 · Reply

Dirtbagg Feb. 19 at 5:11 AM

$CYPH do I see fity or 40s.

0 · Reply

ShyGlizzy Feb. 18 at 8:59 PM

$CYPH congratulations to whoever took my short at the top $3. you are now up 3029%

0 · Reply

fivehundredpercent Feb. 18 at 8:52 PM

$CYPH They will send this back over 1 and eventually over 3 again

0 · Reply

StockDreamin Feb. 18 at 8:16 PM

$CYPH cypherslump

0 · Reply

fivehundredpercent Feb. 18 at 8:04 PM

$CYPH just see this down 17% its all shorts so I will take some .60s and bidding more lower maybe I get lucky

0 · Reply

Cwise59 Feb. 18 at 7:48 PM

$CYPH bear trap. Back to .70+

0 · Reply

StockDreamin Feb. 18 at 7:38 PM

$CYPH damn...thought i was getting a deal at 64

0 · Reply

StockDreamin Feb. 18 at 6:38 PM

$CYPH sinky sinky

0 · Reply

DubLad76 Feb. 18 at 6:10 PM

$CYPH

0 · Reply

IonutDeica Feb. 18 at 5:29 PM

$CYPH

0 · Reply

atechniqueisause Feb. 18 at 4:20 PM

$CYPH Let me ask again: How will value be created and/or increase here? Remind me again why Winklevoss invested? And why should someone be hopeful to profit here someday? No joke, no sarcasm, it's a serious question.

1 · Reply

DubLad76 Feb. 18 at 1:04 PM

$CYPH boom! 💥 let’s go go go!

0 · Reply

StockDreamin Feb. 18 at 2:43 AM

$CYPH lets go

0 · Reply

Market Cap	27.75M
Revenue (ttm)	0.00
Net Income (ttm)	-67.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	897,500
Avg Vol	4,216,646
Day's Range	N/A - N/A
Shares Out	41.44M
Stochastic %K	43%
Beta	-0.19
Analysts	Strong Buy
Price Target	N/A